| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1/2 data readout example | CpG 1018 adjuvanted H5N1 influenza vaccine pandemic influenza | Phase 1/2 | — | Vaccines | Infectious Diseases | ||
Phase 1/2 data readout example | CpG 1018 adjuvanted H5N1 influenza vaccine pandemic influenza | Phase 1/2 | — | Vaccines | Infectious Diseases | ||
Phase 1/2 data readout example | CpG 1018 adjuvanted H5N1 influenza vaccine pandemic influenza | Phase 1/2 | — | Vaccines | Infectious Diseases |
Recent Updates
Recently added Catalysts
Dynavax Technologies Corporation$15.5
+0.01 (+0.06%)
C 49Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.82 B
EPS
-0.33
P/E Ratio
-
Value Trade
110.13 M
0.13 %
Week
0.52 %
1 Month
40.27 %
3 Month
45.54 %
6 Month
44.86 %
5 Year
-81.87 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
7.11 M
52 Week Range
9.20 - 15.73
% held by Insiders
0.81 %
% held by Institutions
97.03 %
Enterprise Value
1.46 B
Total Shares
117.28 M
Short %
8.69 %
Float Shares
112.71 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C49
Pipeline Score $1.6B
Pipeline ValueFair Value
Valuation Signal13
Drugs Scored0.9x
rNPV / MCap Top 75%
Micro Cap (rank 227 of 905)
Percentile RankDynavax Technologies Corporation carries a moderate pipeline score (49/100), with $4.8B risk-adjusted pipeline value, led by BG505 SOSIP.664 gp140 in HIV Infections (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BG505 SOSIP.664 gp140 Monoclonal antibody | HIV Infections | Phase 1 | NCT04177355 | 43% | $2.4B | COMPLETED | 127 | - | - | Nov 4, 2024 | - | Sep 2, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
HEPLISAV-B | Hepatitis B | Phase 1/2 | 2025-08-07 | |||
HEPLISAV-B | Hepatitis B | Phase 1/2 | 2025-08-07 | |||
HEPLISAV-B | Hepatitis B | Phase 1/2 | 2025-08-07 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DVAX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
DVAX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DVAX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DVAX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
DVAX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
DVAX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How DVAX ranks across every disease it competes inCompetitive Position is a premium feature
See how DVAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial